120 related articles for article (PubMed ID: 3109738)
1. A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.
Wagstaff J; Smith D; Nelmes P; Loynds P; Crowther D
Cancer Immunol Immunother; 1987; 25(1):54-8. PubMed ID: 3109738
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects.
Thompson JA; Cox WW; Lindgren CG; Collins C; Neraas KA; Bonnem EM; Fefer A
Cancer Immunol Immunother; 1987; 25(1):47-53. PubMed ID: 3109737
[TBL] [Abstract][Full Text] [Related]
3. A phase I clinical trial of recombinant DNA gamma interferon.
Brown TD; Koeller J; Beougher K; Golando J; Bonnem EM; Spiegel RJ; Von Hoff DD
J Clin Oncol; 1987 May; 5(5):790-8. PubMed ID: 3106584
[TBL] [Abstract][Full Text] [Related]
4. A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.
Sriskandan K; Garner P; Watkinson J; Pettingale KW; Brinkley D; Calman FM; Tee DE
Cancer Chemother Pharmacol; 1986; 18(1):63-8. PubMed ID: 3093108
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of recombinant human gamma interferon (IFN-gamma 4A) in patients with advanced malignancy.
Perez R; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL; Giudice G; Downing MR; Alton NK
J Biol Response Mod; 1988 Jun; 7(3):309-17. PubMed ID: 3134513
[TBL] [Abstract][Full Text] [Related]
7. Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine.
Bennett CL; Vogelzang NJ; Ratain MJ; Reich SD
Cancer Treat Rep; 1986 Sep; 70(9):1081-4. PubMed ID: 3091246
[TBL] [Abstract][Full Text] [Related]
8. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients.
Boue F; Pastran Z; Spielmann M; Le Chevalier T; Subirana R; Sevin D; Paoletti C; Brandely M; Avril MF; Sancho-Garnier H
Cancer Immunol Immunother; 1990; 32(1):67-70. PubMed ID: 2126985
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
12. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma.
Creagan ET; Ahmann DL; Long HJ; Frytak S; Sherwin SA; Chang MN
Cancer Treat Rep; 1987 Sep; 71(9):843-4. PubMed ID: 3113730
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
Schiller JH; Storer B; Willson JK; Borden EC
Cancer Treat Rep; 1987 Oct; 71(10):945-52. PubMed ID: 3115570
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Farace F; Mathiot C; Brandely M; Tursz T; Dorval T; Pouillart P; Triebel F; Hercend T; Fridman WH
Clin Exp Immunol; 1990 Nov; 82(2):194-9. PubMed ID: 2122928
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.
Schiller JH; Witt PL; Storer B; Alberti D; Tombes MB; Arzoomanian R; Brown RR; Proctor RA; Voss SD; Spriggs DR
Cancer; 1992 Jan; 69(2):562-71. PubMed ID: 1728387
[TBL] [Abstract][Full Text] [Related]
17. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
Grem JL; McAtee N; Murphy RF; Balis FM; Cullen E; Chen AP; Hamilton JM; Steinberg SM; Quinn M; Sorensen JM; Arbuck SG; Lawrence D; Pang J; Allegra CJ
Clin Cancer Res; 1997 Jul; 3(7):1125-34. PubMed ID: 9815792
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of recombinant gamma interferon in patients with cancer.
Foon KA; Sherwin SA; Abrams PG; Stevenson HC; Holmes P; Maluish AE; Oldham RK; Herberman RB
Cancer Immunol Immunother; 1985; 20(3):193-7. PubMed ID: 3933818
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
